Stefan A Laufer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/934192/publications.pdf

Version: 2024-02-01

382	13,208	20817 60	34986 98
papers	citations	h-index	g-index

410	410	410	18586
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design and Synthesis of Highly Selective Brain Penetrant p38Î± Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 1225-1242.	6.4	7
2	Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy. Journal of Medicinal Chemistry, 2022, 65, 955-982.	6.4	48
3	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3Î² Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 1283-1301.	6.4	9
4	Chemical Probes for Understudied Kinases: Challenges and Opportunities. Journal of Medicinal Chemistry, 2022, 65, 1132-1170.	6.4	15
5	Design of a â€œTwo-in-Oneâ€•Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. Journal of Medicinal Chemistry, 2022, 65, 1370-1383.	6.4	13
6	High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. Journal of Medicinal Chemistry, 2022, 65, 1505-1524.	6.4	3
7	Decisive role of water and protein dynamics in residence time of p38Î± MAP kinase inhibitors. Nature Communications, 2022, 13, 569.	12.8	17
8	Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 3173-3192.	6.4	9
9	In vitro and in vivo anti-inflammatory and anticoagulant activities of Myrciaria plinioides D. Legrand ethanol leaf extract. Inflammopharmacology, 2022, 30, 565-577.	3.9	1
10	Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2022, 65, 4616-4632.	6.4	12
11	Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells. International Journal of Molecular Sciences, 2022, 23, 2914.	4.1	16
12	ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury. Nature Communications, 2022, 13, 1823.	12.8	13
13	Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity. European Journal of Medicinal Chemistry, 2022, 235, 114234.	5.5	5
14	New Horizons in Drug Discovery - Understanding and Advancing Different Types of Kinase Inhibitors: Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects. Journal of Medicinal Chemistry, 2022, 65, 891-892.	6.4	9
15	Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TÃ¼KIC Library. Cells, 2022, 11, 1299.	4.1	3
16	2,2,2â€Trifluoroethanolâ€mediated hydroarylation of fluorinated alkynes with indoles: Application to diindolylmethanes. Archiv Der Pharmazie, 2022, 355, e2100488.	4.1	2
17	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ”€What Is Expected?. Journal of Medicinal Chemistry, 2022, 65, 6973-6974.	6.4	10
18	Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts. Future Medicinal Chemistry, 2022, 14, 899-913.	2.3	3

#	Article	IF	Citations
19	Discrepancy in interactions and conformational dynamics of pregnaneÂXÂreceptor (PXR) bound to an agonist and a novel competitive antagonist. Computational and Structural Biotechnology Journal, 2022, 20, 3004-3018.	4.1	4
20	Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structureâ€“Activity Relationships, Antiviral Activity, and X-ray Structure Determination. Journal of Medicinal Chemistry, 2022, 65, 9376-9395.	6.4	35
21	Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114584.	5.5	3
22	Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells. ACS Pharmacology and Translational Science, 2022, 5, 573-602.	4.9	4
23	Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4. European Journal of Medicinal Chemistry, 2021, 209, 112901.	5.5	5
24	From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4). European Journal of Medicinal Chemistry, 2021, 210, 112963.	5.5	8
25	Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19. Stem Cell Reviews and Reports, 2021, 17, 44-55.	3.8	11
26	N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine. MolBank, 2021, 2021, M1181.	0.5	1
27	LXRÎ± activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nature Cancer, 2021, 2, 201-217.	13.2	27
28	A Highly Selective In Vitro JNK3 Inhibitor, FMU200, Restores Mitochondrial Membrane Potential and Reduces Oxidative Stress and Apoptosis in SH-SY5Y Cells. International Journal of Molecular Sciences, 2021, 22, 3701.	4.1	22
29	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery. ChemMedChem, 2021, 16, 1737-1740.	3.2	7
30	A Special View of What Was Almost Forgotten: p38Î´ MAPK. Cancers, 2021, 13, 2077.	3.7	10
31	Synthesis, Characterization, and inâ€…vivo Distribution of Intracellular Delivered Macrolide Shortâ€Chain Fatty Acid Derivatives. ChemMedChem, 2021, 16, 2254-2269.	3.2	7
32	Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. Inflammopharmacology, 2021, 29, 595-615.	3.9	10
33	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery, 2021, 16, 1091-1103.	5.0	6
34	Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration. European Journal of Medicinal Chemistry, 2021, 218, 113371.	5.5	15
35	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. Scientific Reports, 2021, 11, 11998.	3.3	17
36	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	6.4	0

#	Article	IF	Citations
37	Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents. Molecules, 2021, 26, 4065.	3.8	14
38	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. Angewandte Chemie - International Edition, 2021, 60, 20178-20183.	13.8	23
39	Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling. Organic Process Research and Development, 2021, 25, 1831-1840.	2.7	1
40	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. Angewandte Chemie, 2021, 133, 20340-20345.	2.0	2
41	Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe. Journal of Medicinal Chemistry, 2021, 64, 13451-13474.	6.4	4
42	Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals, 2021, 14, 933.	3.8	10
43	Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2). Cancers, 2021, 13, 5133.	3.7	5
44	Biosynthesis of iron oxide magnetic nanoparticles using clinically isolated Pseudomonas aeruginosa. Scientific Reports, 2021, 11, 20503.	3.3	14
45	Methacryloyl-GlcNAc Derivatives Copolymerized with Dimethacrylamide as a Novel Antibacterial and Biocompatible Coating. Pharmaceutics, 2021, 13, 1647.	4.5	4
46	The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma. Pathology and Oncology Research, 2020, 26, 985-995.	1.9	0
47	Neuroprotective potential of Myrciaria plinioides D. Legrand extract in an in vitro human neuroblastoma model. Inflammopharmacology, 2020, 28, 737-748.	3.9	8
48	Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors. European Journal of Medicinal Chemistry, 2020, 187, 112004.	5.5	3
49	Selective targeting of the Î±C and DFG-out pocket in p38 MAPK. European Journal of Medicinal Chemistry, 2020, 208, 112721.	5.5	12
50	New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7921-7922.	6.4	4
51	Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships. European Journal of Medicinal Chemistry, 2020, 204, 112641.	5.5	4
52	Chemical Space Exploration of Oxetanes. International Journal of Molecular Sciences, 2020, 21, 8199.	4.1	3
53	Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome. Data in Brief, 2020, 32, 106189.	1.0	5
54	The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes. ChemMedChem, 2020, 15, 2388-2390.	3.2	11

#	Article	IF	Citations
55	Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay. Journal of Nanobiotechnology, 2020, 18, 130.	9.1	16
56	c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimerâ€™s Diseases. International Journal of Molecular Sciences, 2020, 21, 9677.	4.1	28
57	Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. International Journal of Molecular Sciences, 2020, 21, 9269.	4.1	16
58	Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3Î² Inhibitors with Improved Metabolic Stability. International Journal of Molecular Sciences, 2020, 21, 7823.	4.1	6
59	Antimicrobial and antileukemic effects: in vitro activity of Calyptranthes grandifolia aqueous leaf extract. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 289-301.	2.3	20
60	Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38Î± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7347-7354.	6.4	14
61	Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 4293-4305.	6.4	33
62	An updated patent review of p38 MAP kinase inhibitors (2014-2019). Expert Opinion on Therapeutic Patents, 2020, 30, 453-466.	5.0	53
63	Mapping the S1 and S1â€™ subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents. PLoS Neglected Tropical Diseases, 2020, 14, e0007755.	3.0	11
64	Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research, 2020, 157, 104859.	7.1	426
65	Dapsone is not a Pharmacodynamic Lead Compound for its Aryl Derivatives. Current Computer-Aided Drug Design, 2020, 16, 327-339.	1.2	2
66	In vitro activities of Ceiba speciosa (A.St.-Hil) Ravenna aqueous stem bark extract. Natural Product Research, 2019, 33, 3441-3444.	1.8	8
67	Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3Î² Inhibitors. Molecules, 2019, 24, 2331.	3.8	11
68	Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 10757-10782.	6.4	18
69	Pyridinylimidazoles as GSK3Î² Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks. ACS Medicinal Chemistry Letters, 2019, 10, 1407-1414.	2.8	12
70	Discovery of potent p38Î± MAPK inhibitors through a funnel like workflow combining in silico screening and inÂvitro validation. European Journal of Medicinal Chemistry, 2019, 182, 111624.	5.5	17
71	Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions. Theranostics, 2019, 9, 3903-3917.	10.0	16
72	Visual aptamer-based capillary assay for ethanolamine using magnetic particles and strand displacement. Mikrochimica Acta, 2019, 186, 690.	5.0	8

#	Article	IF	Citations
73	A smartphone readout system for gold nanoparticle-based lateral flow assays: application to monitoring of digoxigenin. Mikrochimica Acta, 2019, 186, 119.	5.0	48
74	An aptamer based thermofluorimetric assay for ethanolamine. Biochimie, 2019, 158, 233-237.	2.6	5
75	Data for homogeneous thermofluorimetric assays for ethanolamine using aptamers and a PCR instrument. Data in Brief, 2019, 24, 103946.	1.0	0
76	Pyridinylimidazoles as dual glycogen synthase kinase 3Î²/p38Î± mitogen-activated protein kinase inhibitors. European Journal of Medicinal Chemistry, 2019, 175, 309-329.	5.5	26
77	Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis. Inflammopharmacology, 2019, 27, 1217-1227.	3.9	10
78	Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms. International Immunopharmacology, 2019, 72, 31-39.	3.8	35
79	Are peptides a solution for the treatment of hyperactivated JAK3 pathways?. Inflammopharmacology, 2019, 27, 433-452.	3.9	4
80	N1-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine. MolBank, 2019, 2019, M1048.	0.5	1
81	Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. Journal of Medicinal Chemistry, 2019, 62, 5673-5724.	6.4	415
82	Synthesis and structureâ€'activityâ€'relationship of 3,4â€'Diarylâ€'1Hâ€'pyrrolo[2,3â€'b]pyridines as irreversible Inhibitors of mutant EGFRâ€'L858R/T790M. European Journal of Pharmaceutical Sciences, 2019, 128, 91-96.	4.0	8
83	Myricetin inhibits panel of kinases implicated in tumorigenesis. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 3-7.	2.5	14
84	Adjunctive role of Calyptranthes tricona extract with probiotic Kluyveromyces marxianus on colorectal adenocarcinoma Caco-2 cells. Phytochemistry Letters, 2019, 30, 1-5.	1.2	2
85	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	3.3	28
86	Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. Angewandte Chemie, 2018, 130, 4456-4470.	2.0	9
87	NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation. European Journal of Medicinal Chemistry, 2018, 153, 73-104.	5.5	13
88	The Cysteinome of Protein Kinases as a Target in Drug Development. Angewandte Chemie - International Edition, 2018, 57, 4372-4385.	13.8	173
89	Development, Optimization, and Structureâ€"Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold. Journal of Medicinal Chemistry, 2018, 61, 5350-5366.	6.4	46
90	Donated chemical probes for open science. ELife, 2018, 7, .	6.0	80

#	Article	IF	Citations
91	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1073-1088.	0.8	3
92	A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38Î± Mitogen-Activated Protein Kinase Inhibitors. Molecules, 2018, 23, 221.	3.8	6
93	Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38Î± Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3. ACS Omega, 2018, 3, 7809-7831.	3.5	24
94	In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species Generation. Journal of Nuclear Medicine, 2017, 58, 853-860.	5.0	19
95	Optimized Target Residence Time: Typeâ€…I Inhibitors for p38Î± MAP Kinase with Improved Binding Kinetics through Direct Interaction with the Râ€Spine. Angewandte Chemie - International Edition, 2017, 56, 5363-5367.	13.8	20
96	Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping. Journal of Medicinal Chemistry, 2017, 60, 4636-4656.	6.4	56
97	Proteasome Activation by Small Molecules. Cell Chemical Biology, 2017, 24, 725-736.e7.	5.2	113
98	Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. Journal of Medicinal Chemistry, 2017, 60, 5613-5637.	6.4	77
99	Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38Î± MAPK/PDE-4 Inhibitor with Activity against TNFÎ±-Related Diseases. Journal of Medicinal Chemistry, 2017, 60, 5290-5305.	6.4	18
100	Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3. Journal of Medicinal Chemistry, 2017, 60, 594-607.	6.4	46
101	Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. Angewandte Chemie - International Edition, 2017, 56, 15504-15505.	13.8	26
102	Design, Synthesis, and Biological Evaluation of Novel Type I¹/₂ p38Î± MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. Journal of Medicinal Chemistry, 2017, 60, 8027-8054.	6.4	24
103	Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4229-4237.	2.2	32
104	Optimierte Bindungsdauer am Zielenzym: Typâ€Iâ€Inhibitoren der p38Î±â€MAPâ€Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der Râ€Spine. Angewandte Chemie, 2017, 129, 5448-5453.	2.0	0
105	P38 Kinase, SGK1 and NF-ÎºB Dependent Up-Regulation of Na+/Ca2+ Exchanger Expression and Activity Following TGFÂŸ1 Treatment of Megakaryocytes. Cellular Physiology and Biochemistry, 2017, 42, 2169-2181.	1.6	6
106	Neue Anwendungen der Klickâ€Chemie in Zellbiologie und Wirkstoffentwicklung. Angewandte Chemie, 2017, 129, 15709-15711.	2.0	7
107	Selective p38Î± MAP kinase/MAPK14 inhibition in enzymatically modified LDLâ€stimulated human monocytes: implications for atherosclerosis. FASEB Journal, 2017, 31, 674-686.	0.5	29
108	From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38Î± MAP Kinase Inhibitors. Molecules, 2017, 22, 1729.	3.8	10

#	Article	IF	Citations
109	Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS ONE, 2017, 12, e0181585.	2.5	131
110	Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males. Journal of Clinical Investigation, 2017, 127, 3167-3176.	8.2	75
111	Why Antidiabetic Vanadium Complexes are Not in the Pipeline of â€œBig Pharmaâ€•Drug Research? A Critical Review. Current Medicinal Chemistry, 2016, 23, 2874-2891.	2.4	78
112	Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. Cell Chemical Biology, 2016, 23, 1335-1340.	5.2	96
113	A MYCâ€“aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nature Medicine, 2016, 22, 744-753.	30.7	207
114	Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. Brain, Behavior, and Immunity, 2016, 55, 70-81.	4.1	253
115	ILâ€1Î², ILâ€18, and eicosanoids promote neutrophil recruitment to poreâ€induced intracellular traps following pyroptosis. European Journal of Immunology, 2016, 46, 2761-2766.	2.9	135
116	Neuromodulatory effects of Calyptranthes grandifolia extracts against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Biomedicine and Pharmacotherapy, 2016, 84, 382-386.	5.6	12
117	SCISSORâ€”Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol. BMJ Open, 2016, 6, e010651.	1.9	17
118	Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapyâ€Resistant L858R/T790M/C797S Mutant. Angewandte Chemie - International Edition, 2016, 55, 10890-10894.	13.8	76
119	Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). Future Medicinal Chemistry, 2016, 8, 1537-1551.	2.3	10
120	Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends in Pharmacological Sciences, 2016, 37, 904-932.	8.7	72
121	Lungenkrebs: EGFRâ€Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797Sâ€Mutante.. Angewandte Chemie, 2016, 128, 11050-11054.	2.0	6
122	Stimulating Effect of Sclareol on Suicidal Death of Human Erythrocytes. Cellular Physiology and Biochemistry, 2016, 39, 554-564.	1.6	29
123	11th German Conference on Chemoinformatics (GCC 2015). Journal of Cheminformatics, 2016, 8, 18.	6.1	1
124	Design and Development of Microsomal Prostaglandin E₂ Synthase-1 Inhibitors: Challenges and Future Directions. Journal of Medicinal Chemistry, 2016, 59, 5970-5986.	6.4	63
125	Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity. Carbohydrate Polymers, 2016, 143, 25-34.	10.2	34
126	From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors. Methods in Molecular Biology, 2016, 1360, 123-148.	0.9	10

#	Article	IF	Citations
127	Abstract 257: Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib. , 2016, , .		0
128	Poly[[tetramethanolbis[4-oxo-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-olato]disodium]â€“diethetherâ€“methanol (1/1/2)]. IUCrData, 2016, 1, .	0.3	0
129	Abstract 1257: A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer. , 2016, , .		0
130	Fucoxanthin Induced Suicidal Death of Human Erythrocytes. Cellular Physiology and Biochemistry, 2015, 37, 2464-2475.	1.6	47
131	Triggering of Suicidal Erythrocyte Death by Ruxolitinib. Cellular Physiology and Biochemistry, 2015, 37, 768-778.	1.6	62
132	Role of p38 mitogenâ€activated protein kinase in linking stearoylâ€CoA desaturaseâ€1 activity with endoplasmic reticulum homeostasis. FASEB Journal, 2015, 29, 2439-2449.	0.5	35
133	Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resistance Updates, 2015, 20, 12-28.	14.4	103
134	c-JunN-terminal kinase inhibitors: a patent review (2010 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 849-872.	5.0	47
135	Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-Î± in Whole Blood and Primary Cells from Different Species. Cellular Physiology and Biochemistry, 2015, 36, 2237-2249.	1.6	24
136	Triggering of Suicidal Erythrocyte Death Following Boswellic Acid Exposure. Cellular Physiology and Biochemistry, 2015, 37, 131-142.	1.6	55
137	Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38Î± Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2015, 58, 443-456.	6.4	43
138	New Frontiers in Kinases: Second Generation Inhibitorsâ€“Going beyond Cancer. ACS Medicinal Chemistry Letters, 2015, 6, 1-1.	2.8	0
139	The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogenâ€Activated Protein Kinase Inhibitors. Chemical Biology and Drug Design, 2015, 86, 531-545.	3.2	14
140	New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential. Amino Acids, 2015, 47, 1155-1166.	2.7	12
141	Effect of TGFÎ² on calcium signaling in megakaryocytes. Biochemical and Biophysical Research Communications, 2015, 461, 8-13.	2.1	8
142	An optimized and versatile synthesis to pyridinylimidazole-type p38Î± mitogen activated protein kinase inhibitors. Organic and Biomolecular Chemistry, 2015, 13, 10699-10704.	2.8	4
143	Targeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen Bond. Journal of the American Chemical Society, 2015, 137, 14640-14652.	13.7	73
144	Inhibitors of c-Jun N-Terminal Kinases: An Update. Journal of Medicinal Chemistry, 2015, 58, 72-95.	6.4	81

#	Article	IF	Citations
145	Advancing the Kinase Field: New Targets and Second Generation Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 1-1.	6.4	9
146	Solution-Phase Parallel Synthesis of Ruxolitinib-Derived Janus Kinase Inhibitors via Copper-Catalyzed Azideâ€“Alkyne Cycloaddition. ACS Combinatorial Science, 2015, 17, 5-10.	3.8	14
147	Flavonoids Inhibit COX-1 and COX-2 Enzymes and Cytokine/Chemokine Production in Human Whole Blood. Inflammation, 2015, 38, 858-870.	3.8	92
148	Development of First Lead Structures for Phosphoinositide 3-Kinase-C2Î³ Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 212-221.	6.4	23
149	Influence of annexin A7 on insulin sensitivity of cellular glucose uptake. Pflugers Archiv European Journal of Physiology, 2015, 467, 641-649.	2.8	9
150	Novel Hingeâ€Binding Motifs for Janus Kinaseâ€…3 Inhibitors: A Comprehensive Structureâ€“Activity Relationship Study on Tofacitinib Bioisosteres. ChemMedChem, 2014, 9, 2516-2527.	3.2	28
151	2-(3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}oxetan-3-yl)aceton monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2014, 70, o382-o383.	0.2	1
152	New Frontiers in Kinases: Second Generation Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 2167-2168.	6.4	24
153	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2014, 71, 1-14.	5.5	109
154	Discovery of a Novel Series of Tetrahydroâ€Îµâ€carbolines Inducing Autophagic Cell Death in Human Metastatic Melanoma. Archiv Der Pharmazie, 2014, 347, 398-406.	4.1	2
155	Antinociceptive, anti-inflammatory and gastroprotective effects of a hydroalcoholic extract from the leaves of Eugenia punicifolia (Kunth) DC. in rodents. Journal of Ethnopharmacology, 2014, 157, 257-267.	4.1	24
156	A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors. Analytical Methods, 2014, 6, 8817-8822.	2.7	15
157	Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats. Rheumatology, 2014, 53, 425-432.	1.9	10
158	Interference of Boswellic Acids with the Ligand Binding Domain of the Glucocorticoid Receptor. Journal of Chemical Information and Modeling, 2014, 54, 978-986.	5.4	15
159	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	30.7	242
160	Effect of TGFÎ² on Na+/K+ ATPase activity in megakaryocytes. Biochemical and Biophysical Research Communications, 2014, 452, 537-541.	2.1	5
161	Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes. ChemMedChem, 2014, 9, 277-281.	3.2	32
162	p38 MAPK inhibitors: a patent review (2012 â€“ 2013). Expert Opinion on Therapeutic Patents, 2014, 24, 535-554.	5.0	53

#	Article	IF	Citations
163	Modeling of Compound Profiling Experiments Using Support Vector Machines. Chemical Biology and Drug Design, 2014, 84, 75-85.	3.2	6
164	Four New Flavonol Glycosides from the Leaves of Brugmansia suaveolens. Molecules, 2014, 19, 6727-6736.	3.8	9
165	Design and Synthesis of Novel Quinazoline Derivatives and Their Evaluation as PI3Ks Inhibitors. Chemical and Pharmaceutical Bulletin, 2014, 62, 1166-1172.	1.3	1
166	A p38 Substrate-Specific MK2-EGFP Translocation Assay for Identification and Validation of New p38 Inhibitors in Living Cells: A Comprising Alternative for Acquisition of Cellular p38 Inhibition Data. PLoS ONE, 2014, 9, e95641.	2.5	7
167	Metabolically Stable Dibenzo[b,e]oxepin-11(6H)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood. Journal of Medicinal Chemistry, 2013, 56, 8561-8578.	6.4	26
168	Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity. Journal of Medicinal Chemistry, 2013, 56, 241-253.	6.4	31
169	Entada africana fraction CH2Cl2/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microglia. BMC Complementary and Alternative Medicine, 2013, 13, 254.	3.7	18
170	A fraction of stem bark extract of Entada africana suppresses lipopolysaccharide-induced inflammation in RAW 264.7 cells. Journal of Ethnopharmacology, 2013, 149, 162-168.	4.1	23
171	Drug Discovery: A Modern Decathlon. Angewandte Chemie - International Edition, 2013, 52, 4072-4076.	13.8	12
172	Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. Journal of Lipid Research, 2013, 54, 3116-3129.	4.2	31
173	Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation. Cellular Physiology and Biochemistry, 2013, 31, 914-924.	1.6	1,301
174	Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2546-2551.	7.1	80
175	Synthesis, p38 Kinase Inhibitory and Anti-inflammatory Activity of New Substituted Benzimidazole Derivatives. Medicinal Chemistry, 2013, 9, 91-99.	1.5	13
176	Deoxyhypusine Hydroxylase from Plasmodium vivax, the Neglected Human Malaria Parasite: Molecular Cloning, Expression and Specific Inhibition by the 5-LOX Inhibitor Zileuton. PLoS ONE, 2013, 8, e58318.	2.5	14
177	A New In Vitro Model to Study Cellular Responses after Thermomechanical Damage in Monolayer Cultures. PLoS ONE, 2013, 8, e82635.	2.5	17
178	Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H567-H581.	3.2	12
179	4-(4-Fluorophenyl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o632-o632.	0.2	6
180	Ethyl 5-amino-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o917-o918.	0.2	3

#	Article	IF	Citations
181	4-[5-Amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl]benzonitrile. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o935-o935.	0.2	2
182	4-(4-Fluorophenyl)-1-(4-nitrophenyl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o633-o633.	0.2	7
183	4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o2603-o2603.	0.2	3
184	N-[(3RS,4RS)-1-Benzyl-4-methylpiperidin-3-yl]-5-nitro-1-phenylsulfonyl-1H-pyrrolo[2,3-b]pyridine-4-amine. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o3051-o3051.	0.2	1
185	1-[(3RS,4RS)-1-Benzyl-4-methylpiperidin-3-yl]-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine hemihydrate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o3052-o3052.	0.2	1
186	2-[5-Bromo-1-(3-chlorobenzyl)-2-methyl-1H-indol-3-yl]acetic acid. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o3396-o3396.	0.2	0
187	3-(4-Bromophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o3397-o3397.	0.2	0
188	Assessing the Target Differentiation Potential of Imidazole-Based Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 11067-11071.	6.4	24
189	The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. Cancer Letters, 2012, 321, 187-194.	7.2	34
190	Zur Reaktion von Triphenylphosphan mit Thionylchlorid. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2012, 638, 1784-1786.	1.2	3
191	Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases. Journal of Medicinal Chemistry, 2012, 55, 961-965.	6.4	70
192	Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases. RSC Drug Discovery Series, 2012, , 137-157.	0.3	1
193	Identification of new Î³-hydroxybutenolides that preferentially inhibit the activity of mPGES-1. Bioorganic and Medicinal Chemistry, 2012, 20, 5012-5016.	3.0	10
194	A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 8429-8439.	6.4	28
195	Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38Î± Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7862-7874.	6.4	36
196	Modified Acidic Nonsteroidal Anti-Inflammatory Drugs as Dual Inhibitors of mPGES-1 and 5-LOX. Journal of Medicinal Chemistry, 2012, 55, 8958-8962.	6.4	38
197	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	2.5	21
198	{nBuMg(OR)}₂ und {Mg(OR)₂}₂ (R = 2,) Tj ETQq0 0 0 rgBT /Overloc Magnesiumalkoholate. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2012, 638, 730-732.	1.2	5

#	Article	IF	Citations
199	Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nature Chemical Biology, 2012, 8, 141-143.	8.0	109
200	Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase. Journal of Medicinal Chemistry, 2012, 55, 5868-5877.	6.4	31
201	Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. European Journal of Pharmacology, 2012, 674, 143-152.	3.5	21
202	Development of a p38Î´ mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor activity. Journal of Pharmaceutical and Biomedical Analysis, 2012, 66, 349-351.	2.8	7
203	Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action. Phytochemistry, 2012, 78, 107-119.	2.9	60
204	A Multicomponent Carbaâ€Betti Strategy to Alkylidene Heterodimers â€“ Total Synthesis and Structureâ€“Activity Relationships of Arzanol. European Journal of Organic Chemistry, 2012, 2012, 772-779.	2.4	27
205	Inferential NMR/Xâ€rayâ€Based Structure Determination of a Dibenzo[a,d]cycloheptenone Inhibitorâ€“p38Î± MAP Kinase Complex in Solution. Angewandte Chemie - International Edition, 2012, 51, 2359-2362.	13.8	11
206	Conformational effects on potency of thioimidazoles and dihydrothiazolines. MedChemComm, 2011, 2, 261.	3.4	7
207	Modeling and Benchmark Data Set for the Inhibition of c-Jun N-terminal Kinase-3. Journal of Chemical Information and Modeling, 2011, 51, 670-679.	5.4	6
208	Chiral Sulfoxides as Metabolites of 2-Thioimidazole-Based p38Î± Mitogen-Activated Protein Kinase Inhibitors: Enantioselective Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2011, 54, 3283-3297.	6.4	25
209	Structural and Conformational Analysis of Proanthocyanidins from Parapiptadenia rigida and Their Wound-Healing Properties. Journal of Natural Products, 2011, 74, 1427-1436.	3.0	15
210	The application of Stille cross-coupling reactions with multiple nitrogen containing heterocycles. Tetrahedron, 2011, 67, 9204-9213.	1.9	8
211	p38Î± mitogen-activated protein kinase inhibitors, a patent review (2005 â€“ 2011). Expert Opinion on Therapeutic Patents, 2011, 21, 1843-1866.	5.0	23
212	A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 236-240.	2.8	21
213	Alkoxymagnesium Iodide Complexes. European Journal of Inorganic Chemistry, 2011, 2011, 3284-3287.	2.0	3
214	Design, Synthesis and Structureâ€“Activity Relationship of Functionalized Tetrahydroâ€Î²â€carboline Derivatives as Novel PDE5 Inhibitors. Archiv Der Pharmazie, 2011, 344, 149-157.	4.1	24
215	Transient exposure of macrophages to P38 map kinase inhibition conditions cell responses through MAPK activated protein kinase-2 regulation. Annals of the Rheumatic Diseases, 2011, 70, A17-A17.	0.9	0
216	3-(2,4-Dimethoxyanilino)-8-methoxydibenz[b,e]oxepin-11(6H)-one. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o487-o487.	0.2	0

#	Article	IF	Citations
217	1,4-Dimethyl-2-phenyl-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-3,5(2H,4H)-dione. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2586-o2586.	0.2	0
218	3-(2,4-Difluoroanilino)-9-nitrodibenzo[b,e]oxepin-11(6H)-one. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o555-o555.	0.2	0
219	6-(4-Chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-carbaldehyde. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2292-o2292.	0.2	0
220	6-(4-Methoxyphenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-carbaldehyde. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2417-o2417.	0.2	0
221	Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European Journal of Pharmacology, 2010, 635, 212-218.	3.5	28
222	Synthesis and Biological Testing of Nâ€Aminoimidazoleâ€Based p38Î± MAP Kinase Inhibitors. ChemMedChem, 2010, 5, 1134-1142.	3.2	16
223	Biological Evaluation and Structural Determinants of p38Î± Mitogenâ€Activatedâ€Protein Kinase and câ€Junâ€Nâ€Terminal Kinase 3 Inhibition by Flavonoids. ChemBioChem, 2010, 11, 2579-2588.	2.6	34
224	Fluorescence polarization binding assay to develop inhibitors of inactive p38Î± mitogen-activated protein kinase. Analytical Biochemistry, 2010, 401, 125-133.	2.4	19
225	Optimization of a nonradioactive immunosorbent assay for p38Î± mitogen-activated protein kinase activity. Analytical Biochemistry, 2010, 406, 233-234.	2.4	37
226	Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3074-3077.	2.2	24
227	Tri- and tetrasubstituted imidazoles as p38Î± mitogen-activated protein kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6671-6675.	2.2	36
228	2-(4-Fluorophenyl)-N-{4-[6-(4-fluorophenyl)-2,3-dihydroimidazo[2,1-b][1,3]thiazol-5-yl]pyridin-2-yl}acetamide. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1132-o1132.	0.2	3
229	N-[3-(5-Oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-ylamino)phenyl]furan-3-carboxamide. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1100-o1100.	0.2	0
230	2-(Bicyclo[2.2.1]hept-5-en-2-yl)-1H-pyrrolo[2,3-b]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1800-o1800.	0.2	0
231	N-{2-Methyl-5-[(5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)amino]phenyl}benzamide. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1867-o1867.	0.2	0
232	N-(4-Chloropyridin-2-yl)-N-(4-methylphenylsulfonyl)acetamide. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o3320-o3320.	0.2	0
233	N-(4-Chloropyridin-2-yl)-N-methoxymethyl-4-methylbenzenesulfonamide. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o3321-o3321.	0.2	0
234	1-[4-(2-Aminoanilino)phenyl]-2,2,2-trifluoroethanone. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1149-o1149.	0.2	0

#	Article	IF	Citations
235	Unexpected Reaction of 2-Alkylsulfanylimidazoles to Imidazol-2-ones: Pyridinylimidazol-2-ones as Novel Potent p38Î± Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 4798-4802.	6.4	15
236	Pyridinylquinoxalines and Pyridinylpyridopyrazines as Lead Compounds for Novel p38Î± Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 1128-1137.	6.4	28
237	Identification of rosmarinic acid as the major active constituent in Cordia americana. Journal of Ethnopharmacology, 2010, 128, 561-566.	4.1	27
238	Different Methods for Testing Potential Cyclooxygenase-1 and Cyclooxygenase-2 Inhibitors. Methods in Molecular Biology, 2010, 644, 91-116.	0.9	15
239	Catechin Derivatives from Parapiptadenia rigida with in Vitro Wound-Healing Properties. Journal of Natural Products, 2010, 73, 2035-2041.	3.0	45
240	One-Pot Synthesis of 4,6-Diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38Î± MAP Kinase Inhibition. ACS Combinatorial Science, 2010, 12, 559-565.	3.3	19
241	N-{4-[4-(4-Fluorophenyl)-1-methyl-2-[(R)-methylsulfinyl]-1H-imidazol-5-yl]-2-pyridyl}acetamide dihydrate. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o121-o121.	0.2	1
242	5-(4-Fluorophenyl)-4-(4-pyridyl)-1,3-oxazol-2-amine. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o917-o917.	0.2	1
243	7-[4-(4-Fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl]tetrazolo[1,5-a]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o451-o451.	0.2	0
244	4-Chloro-7-methoxymethyl-2-phenyl-7H-pyrrolo[2,3-b]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o822-o822.	0.2	0
245	Influence of p38MAPK inhibition on IL-1Î²-stimulated human chondrocytes: A microarray approach. International Journal of Molecular Medicine, 2009, 23, 685-93.	4.0	9
246	Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Annals of the Rheumatic Diseases, 2009, 68, 938-947.	0.9	143
247	Accelerated Clearance of Plasmodium-infected Erythrocytes in Sickle Cell Trait and Annexin-A7 Deficiency. Cellular Physiology and Biochemistry, 2009, 24, 415-428.	1.6	128
248	Successful Structure-Based Design of Recent p38 MAP Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2009, 9, 655-676.	2.1	40
249	Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer, 2009, 9, 104.	2.6	65
250	2â€Acylaminopyridinâ€4â€ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations. ChemMedChem, 2009, 4, 1939-1948.	3.2	29
251	Rapid and easy access to indoles via microwave-assisted Hemetsbergerâ€“Knittel synthesis. Tetrahedron Letters, 2009, 50, 1708-1709.	1.4	29
252	Colocalization of the VEGFâ€R2 and the common ILâ€3/GMâ€CSF receptor beta chain to lipid rafts leads to enhanced p38 activation. British Journal of Haematology, 2009, 145, 399-411.	2.5	19

#	Article	IF	Citations
253	Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1461-1464.	2.2	15
254	Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1788-1793.	5.5	13
255	Role of the Hydrogen Bonding Heteroatomâ^'Lys53 Interaction between the p38Î± Mitogen-Activated Protein (MAP) Kinase and Pyridinyl-Substituted 5-Membered Heterocyclic Ring Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2613-2617.	6.4	32
256	Biological studies on Brazilian plants used in wound healing. Journal of Ethnopharmacology, 2009, 122, 523-532.	4.1	107
257	Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts. Journal of Ethnopharmacology, 2009, 126, 463-467.	4.1	259
258	Arylpyrrolizines as Inhibitors of Microsomal Prostaglandin E₂ Synthase-1 (mPGES-1) or as Dual Inhibitors of mPGES-1 and 5-Lipoxygenase (5-LOX). Journal of Medicinal Chemistry, 2009, 52, 4968-4972.	6.4	64
259	Novel Lead Structures for p38 MAP Kinase via FieldScreen Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 4200-4209.	6.4	46
260	3,4-Diaryl-isoxazoles and -imidazoles as Potent Dual Inhibitors of p38Î± Mitogen Activated Protein Kinase and Casein Kinase 1Î´. Journal of Medicinal Chemistry, 2009, 52, 7618-7630.	6.4	64
261	Aza-Analogue Dibenzepinone Scaffolds as p38 Mitogen-Activated Protein Kinase Inhibitors: Design, Synthesis, and Biological Data of Inhibitors with Improved Physicochemical Properties. Journal of Medicinal Chemistry, 2009, 52, 1778-1782.	6.4	25
262	4-[2-(4-Fluorophenyl)-1H-pyrrol-3-yl]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o457-o457.	0.2	1
263	4-[2-(4-Fluorophenyl)furan-3-yl]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o458-o458.	0.2	1
264	4-[5-(4-Fluorophenyl)-1H-imidazol-4-yl]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o573-o573.	0.2	2
265	2-(4-Fluorophenyl)-3-(4-pyridyl)pyrido[2,3-b]pyrazine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2512-o2512.	0.2	2
266	N-{4-[4-(4-Fluorophenyl)-1-(2-methoxyethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-2-pyridyl}-2-methyl-3-phenylpropionamide. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o3128-o3128.	0.2	1
267	(2Z)-2-Fluoro-N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-2-pyridyl}-3-phenylacrylamide. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o3284-o3284.	0.2	1
268	4-[3-(4-Fluorophenyl)quinoxalin-2-yl]-N-isopropylpyridin-2-amine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o1344-o1344.	0.2	0
269	1-[2-(Benzylamino)-4-pyridyl]-2-(4-fluorophenyl)ethane-1,2-dione. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o1451-o1451.	0.2	0
270	3-(4-Fluorophenyl)-6-methoxy-2-(4-pyridyl)quinoxaline. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o1626-o1626.	0.2	0

#	Article	IF	Citations
271	N-{4-[3-(4-Fluorophenyl)pyrido[2,3-b]pyrazin-2-yl]-2-pyridyl}isopropylamine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2557-o2557.	0.2	1
272	3-(4-Fluorophenyl)-2-(4-pyridyl)pyrido[2,3-b]pyrazine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2546-o2546.	0.2	1
273	2-[(1-Methyl-1H-pyrrol-2-yl)carbonylmethyl]isoindoline-1,3-dione. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2375-o2375.	0.2	0
274	4-(4-Fluorophenyl)-1-methoxymethyl-2-phenyl-1H-imidazole. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2803-o2803.	0.2	0
275	4-Chloro-1-(4-methylphenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o3018-o3018.	0.2	0
276	2-(3,4,5-Trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o3097-o3097.	0.2	0
277	Dynamics in the p38Î±â€…MAPâ€…Kinaseâ€“SB203580 Complex Observed by Liquidâ€State NMR Spectroscopy. Angewandte Chemie - International Edition, 2008, 47, 3548-3551.	13.8	25
278	Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis. Journal of the American Society for Mass Spectrometry, 2008, 19, 1500-1513.	2.8	38
279	Implications for selectivity of 3,4-diarylquinolinones as p38Î±MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1431-1435.	2.2	48
280	Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Analytica Chimica Acta, 2008, 618, 29-34.	5.4	41
281	Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers, 2008, 13, 435-449.	1.9	81
282	Inhibition of GSK3 differentially modulates NF-ÎºB, CREB, AP-1 and Î²-catenin signaling in hepatocytes, but fails to promote TNF-Î±-induced apoptosis. Experimental Cell Research, 2008, 314, 1351-1366.	2.6	69
283	Isoxazolone Based Inhibitors of p38 MAP Kinases. Journal of Medicinal Chemistry, 2008, 51, 2580-2584.	6.4	32
284	Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles. Journal of Medicinal Chemistry, 2008, 51, 5630-5640.	6.4	66
285	Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in knee osteoarthritis patients. Arthritis Research and Therapy, 2008, 10, R129.	3.5	34
286	Design, Synthesis, and Biological Evaluation of Novel Tri- and Tetrasubstituted Imidazoles as Highly Potent and Specific ATP-Mimetic Inhibitors of p38 MAP Kinase: Focus on Optimized Interactions with the Enzymeâ€™s Surface-Exposed Front Region. Journal of Medicinal Chemistry, 2008, 51, 4122-4149.	6.4	77
287	Three-Component Combinatorial Synthesis of Novel Dihydropyrano[2,3-c]pyrazoles. ACS Combinatorial Science, 2008, 10, 364-367.	3.3	81
288	Design, Synthesis, and Biological Evaluation of Novel 3-Aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor (VEGF-R) Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3814-3824.	6.4	82

#	Article	IF	Citations
289	Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. Organic and Biomolecular Chemistry, 2008, 6, 437-439.	2.8	33
290	Licofelone Suppresses Prostaglandin E₂ Formation by Interference with the Inducible Microsomal Prostaglandin E₂ Synthase-1. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 975-982.	2.5	156
291	Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis, 2008, 29, 371-380.	2.8	87
292	6-Amino-1-benzyl-4-(4-chlorophenyl)-3-(4-pyridyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o701-o701.	0.2	1
293	In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase. Drug Metabolism and Disposition, 2008, 36, 894-903.	3.3	16
294	A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl)cyclopentene from Cyclopentanone. Synthesis, 2008, 2008, 225-228.	2.3	1
295	Regiospecific and Highly Flexible Synthesis of 1,4,5-Trisubstituted 2-Sulfanylimidazoles from Structurally Diverse Ethanone Precursors. Synthesis, 2008, 2008, 253-266.	2.3	20
296	IL-1Î² Regulates FHL2 and Other Cytoskeleton-Related Genes in Human Chondrocytes. Molecular Medicine, 2008, 14, 150-159.	4.4	36
297	4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-yl]-1-methylpyridinium iodideâ€“4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-4-yl]-1-methylpyridinium iodide (0.6/0.4). Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o298-o299.	0.2	1
298	4-(4-Fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl)isoxazol-5(2H)-one. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o504-o504.	0.2	1
299	tert-ButylN-(4-methyl-2-pyridyl)carbamate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2216-o2216.	0.2	4
300	tert-ButylN-benzyl-N-(4-methyl-2-pyridyl)carbamate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2222-o2222.	0.2	1
301	3-(2-Fluorophenyl)-6-(phenoxymethyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o700-o700.	0.2	2
302	Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl]butanoate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1183-o1184.	0.2	1
303	tert-ButylN-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl]carbamate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2221-o2221.	0.2	0
304	Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor. Drug Metabolism and Disposition, 2007, 35, 875-883.	3.3	21
305	From Five- to Six-Membered Rings:â€‰ 3,4-Diarylquinolinone as Lead for Novel p38MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 1213-1221.	6.4	42
306	Synthesis, Biological Testing, and Binding Mode Prediction of 6,9-Diarylpurin-8-ones as p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 2060-2066.	6.4	23

#	Article	IF	Citations
307	Are MAP Kinases Drug Targets? Yes, but Difficult Ones. ChemMedChem, 2007, 2, 1116-1140.	3.2	40
308	N-{(Z)-2-[1-(Triisopropylsilyl)-1H-indol-3-yl]-2-(triisopropylsilyloxy)vinyl}-2-(3,4,5-trimethoxyphenyl)acetamide. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1266-o1268.	0.2	1
309	(1aR,2aS,5aS,5bS)-Perhydro-4H-oxireno[3,4]cyclopenta[1,2-b]furan-4-one. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1359-o1360.	0.2	0
310	4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridin-2(1H)-one. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1423-o1425.	0.2	3
311	rac-(3E,3aR,6aR)-3-(Hydroxymethylene)-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-one. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1551-o1553.	0.2	0
312	2,2-Dimethyl-N-[3-(3,4,5-trimethoxybenzoyl)pyridin-4-yl]propanamide. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1887-o1889.	0.2	0
313	3-(4-Fluorophenyl)-1-methyl-4-(4-pyridyl)quinolin-2(1H)-one. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o2457-o2459.	0.2	0
314	(2aRS,3RS,4aSR,6aRS,6bSR)-3-Hydroxy-2a,3,4a,6,6a,6b-hexahydro-1,4-dioxacyclopenta[cd]pentalen-2(5H)-one. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o2249-o2251.	0.2	0
315	2-(4-Fluorophenyl)-1-(4-pyridyl)cyclopentan-1-ol. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o3531-o3531.	0.2	0
316	2-(6-Methoxy-7H-purin-7-yl)-1-phenylethanone monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o4154-o4155.	0.2	0
317	2-(6-Amino-7H-purin-7-yl)-1-phenylethanone. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o4646-o4647.	0.2	0
318	Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling. BMC Biochemistry, 2007, 8, 25.	4.4	40
319	Ethyl (2,3-dihydro-1H,1â€²H-2,3â€²-biindol-1-yl)glyoxylate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1415-o1417.	0.2	0
320	Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo[a,d]cycloheptan-5-ones:Â Novel p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 7912-7915.	6.4	40
321	Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5dione (1) as a Highly Selective VEGF-R2/3 Inhibitor. Journal of Medicinal Chemistry, 2006, 49, 7549-7553.	6.4	29
322	3-(4-Fluorophenyl)-4-(4-pyridyl)quinolin-2(1H)-one. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o2475-o2477.	0.2	1
323	4-(4-Fluorophenyl)-3-(4-pyridyl)quinolin-2(1H)-one. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o2648-o2650.	0.2	2
324	4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o3647-o3649.	0.2	1

#	Article	IF	Citations
325	4-[3-(4-Fluorophenyl)-5-isopropylisoxazol-4-yl]pyridine. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o3707-o3709.	0.2	1
326	3,4-Bis(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o4827-o4828.	0.2	1
327	(4R)-4-Hydroxy-1-[(2S)-2-hydroxydodecyl]-L-proline monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o5138-o5140.	0.2	0
328	Quantitative determination of piritramide in human plasma and urine by off- and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 275-283.	1.5	18
329	Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells. Bioorganic and Medicinal Chemistry, 2006, 14, 2487-2497.	3.0	36
330	A concise and optimized four-step approach toward 2-(aryl-)alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles using alkyl- or arylalkyl thiocyanates. Tetrahedron Letters, 2006, 47, 7199-7203.	1.4	28
331	Substituted Isoxazoles as Potent Inhibitors of p38 MAP Kinase. ChemMedChem, 2006, 1, 197-207.	3.2	31
332	Small molecular anti-cytokine agents. Medicinal Research Reviews, 2006, 26, 1-62.	10.5	120
333	New Approaches to the Treatment of Inflammatory Disorders Small Molecule inhibitors of p38 MAP Kinase. Current Topics in Medicinal Chemistry, 2006, 6, 113-149.	2.1	136
334	Stimulation of Suicidal Erythrocyte Death by Lipoxygenase Inhibitor Bay-Y5884. Cellular Physiology and Biochemistry, 2006, 18, 233-242.	1.6	36
335	Development and Optimization of a Non-Radioactive JNK3 Assay. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 613-618.	1.1	5
336	Development of a Microsphere-Based p38Î± Kinase No-Wash Assay. Journal of Biomolecular Screening, 2006, 11, 528-536.	2.6	5
337	MALDI-TOF MS analysis of urinary nucleosides. Journal of the American Society for Mass Spectrometry, 2005, 16, 940-947.	2.8	64
338	An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Analytical Biochemistry, 2005, 344, 135-137.	2.4	43
339	PGE2 in the regulation of programmed erythrocyte death. Cell Death and Differentiation, 2005, 12, 415-428.	11.2	126
340	Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes. Analytical and Bioanalytical Chemistry, 2005, 383, 909-917.	3.7	12
341	Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LCâ€“ITMS coupling. Analytical and Bioanalytical Chemistry, 2005, 382, 1017-1026.	3.7	58
342	Achiralâ€“chiral LC/LCâ€“MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism. Analytical Biochemistry, 2005, 339, 297-309.	2.4	17

#	Article	IF	Citations
343	(3RS,1SR)-3-Bromo-3-(1-phenylpropyl)chroman-2,4-dione. Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o868-o869.	0.2	3
344	Are Vanadium Compounds Drugable? Structures and Effects of Antidiabetic Vanadium Compounds: A Critical Review. Mini-Reviews in Medicinal Chemistry, 2005, 5, 995-1008.	2.4	46
345	Synthesis and Biological Testing of Purine Derivatives as Potential ATP-Competitive Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 710-722.	6.4	89
346	The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Research and Therapy, 2005, 7, R1091.	3.5	56
347	Osteoarthritis therapy–are there still unmet needs?. British Journal of Rheumatology, 2004, 43, 9i-15.	2.3	27
348	The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial. American Journal of Gastroenterology, 2004, 99, 611-618.	0.4	83
349	Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species. Analytical Biochemistry, 2004, 335, 17-29.	2.4	15
350	Determination of(R)- and(S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2004, 18, 458-464.	1.5	13
351	Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B4 in osteoarthritic chondrocytes: Role of transforming growth factor ? and eicosanoids. Arthritis and Rheumatism, 2004, 50, 3925-3933.	6.7	56
352	Tetrasubstituted Imidazole Inhibitors of Cytokine Release:â€‰ Probing Substituents in the N-1 Position. Journal of Medicinal Chemistry, 2004, 47, 6311-6325.	6.4	163
353	The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone, 2004, 34, 527-538.	2.9	143
354	Identification of Regioisomers in a Series of N-Substituted Pyridin-4-yl Imidazole Derivatives by Regiospecific Synthesis, GC/MS, and 1H NMR. Journal of Organic Chemistry, 2003, 68, 4527-4530.	3.2	36
355	Novel Substituted Pyridinyl Imidazoles as Potent Anticytokine Agents with Low Activity against Hepatic Cytochrome P450 Enzymes. Journal of Medicinal Chemistry, 2003, 46, 3230-3244.	6.4	108
356	COX-3: just another COX or the solitary elusive target of paracetamol?. Lancet, The, 2003, 361, 981-982.	13.7	99
357	COXâ€3â€”a virtual pain target in humans?. FASEB Journal, 2003, 17, 2174-2175.	0.5	59
358	International Conference on Inflammopharmacology â€“ VIII Side-Effects of Anti-Inflammatory Drugs Symposium. Expert Opinion on Investigational Drugs, 2003, 12, 1239-1241.	4.1	0
359	Role of eicosanoids in structural degradation in osteoarthritis. Current Opinion in Rheumatology, 2003, 15, 623-627.	4.3	57
360	Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor [alpha] or interleukin 1 [beta] release in vitro and ex vivo. Clinical Pharmacology and Therapeutics, 2003, 73, 272-274.	4.7	15

#	Article	IF	Citations
361	Studies on the Anti-Inflammatory Activity of Phytopharmaceuticals Prepared from Arnica Flowers1. Planta Medica, 2002, 68, 385-391.	1.3	91
362	Imidazole Inhibitors of Cytokine Release:Â Probing Substituents in the 2 Position. Journal of Medicinal Chemistry, 2002, 45, 4695-4705.	6.4	67
363	From Imidazoles to Pyrimidines:â€‰ New Inhibitors of Cytokine Release. Journal of Medicinal Chemistry, 2002, 45, 2733-2740.	6.4	47
364	An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. Osteoarthritis and Cartilage, 2002, 10, 961-967.	1.3	25
365	Ones, Thiones, andN-Oxides: An Exercise in Imidazole Chemistry. Angewandte Chemie - International Edition, 2002, 41, 2290-2293.	13.8	68
366	NO-Donors (VII [1]): Synthesis and Cyclooxygenase Inhibitory Properties of N-and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen â€" A Novel Type of NO-NSAID. Archiv Der Pharmazie, 2002, 335, 363-366.	4.1	14
367	Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis â€" A Review. Archiv Der Pharmazie, 2002, 335, 511-525.	4.1	56
368	Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis and Rheumatism, 2002, 46, 1804-1812.	6.7	64
369	Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. Journal of Rheumatology, 2002, 29, 546-53.	2.0	52
370	Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacological Research, 2001, 43, 429-436.	7.1	139
371	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis and Rheumatism, 2001, 44, 2320-2330.	6.7	100
372	Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl)propanoic Acid (Naproxene) Derivatives. Archiv Der Pharmazie, 2001, 334, 104-106.	4.1	2
373	Discovery and development of ML3000. Inflammopharmacology, 2001, 9, 101-112.	3.9	47
374	Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?. Current Medicinal Chemistry, 2000, 7, 1101-1112.	2.4	108
375	Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 903-906.	2.2	15
376	Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase-1 and 5-Lipoxygenase Inhibitors. Archiv Der Pharmazie, 1997, 330, 307-312.	4.1	25
377	Effiziente Synthese neuer 2â€Cycloalk(en)ylâ€propansÃureâ€Derivate â€" mittlere und groÃŸe Ringe als Bioisostere von Alkylphenylresten?. Angewandte Chemie, 1996, 108, 1312-1314.	2.0	6
378	Efficient Synthesis of New 2-Cycloalk(en)ylpropanoic Acid Derivativesâ€"Medium and Large Rings as Bioisosteres of Alkylphenyl Moieties?. Angewandte Chemie International Edition in English, 1996, 35, 1221-1223.	4.4	6

#	Article	IF	Citations
379	Regioisomeric 5(3)-Aminomethyl-3(5)-phenylisoxazoles: Synthesis, Spectroscopic Discrimination, and Muscarinic Activity. Archiv Der Pharmazie, 1995, 328, 437-443.	4.1	3
380	(6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, a Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase. Journal of Medicinal Chemistry, 1994, 37, 1894-1897.	6.4	118
381	5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidinen. Synthesis, 1989, 1989, 12-15.	2.3	6
382	Multi-gram Preparation of 7-Nitroquinoxalin-2-amine. Journal of the Brazilian Chemical Society, 0, , .	0.6	0